WHERE YOU CAN REQUEST MORE INFORMATION
If you would like more information, please email us at invest@sklip.ai or to schedule a phone call/zoom for more information.
Sklip, Inc. (“the Company”) has a goal to achieve health equity through democratization of skin cancer triage and early diagnosis that may lead to significant reduction in global patient costs, morbidity and mortality of skin cancers such as melanoma, basal cell carcinoma and squamous cell carcinoma.
Sklip Ai accelerates non-invasive skin cancer triage time from days to seconds, increases procedure-related revenue for dermatology offices, reduces dermatology visit wait times from months to days, eliminates primary care referrals requirements, and connects worried consumers to Sklip verified dermatology offices where they can get a visit in under 14 days.
Sklip is a software-based digital health platform app that incorporates our subscription-based, proprietary Ai-driven software with FDA Breakthrough Designation Status. Our patent pending hardware smartphone attachment lets any user take FDA Class 1 medical grade images of a concerning skin lesion (mole). TAM is 58 million American skin cancer survivors and over 2 million medical professionals in the United States and Europe.